S Duarte, BSc
From NAFLD to NASH: Determining Disease Progression and Regression Rates
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s progressive and inflammatory subtype, and 3) NAFLD or NASH with fibrosis, whose stages range from F0-4.
Read MoreFrom NAFLD to NASH: Determining Disease Progression and Regression RatesThe Power of PPARs in NASH-associated Microvascular Dysfunction
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD).
Read MoreThe Power of PPARs in NASH-associated Microvascular DysfunctionPhospholipid Depletion and NAFLD Pathophysiology: Findings from Lipidomics
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
Read MorePhospholipid Depletion and NAFLD Pathophysiology: Findings from LipidomicsNoninvasive Tests for NAFLD: Where Are We Now?
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk of fibrosis and associated adverse outcomes. As such, ensuring the early identification of NAFLD and NASH in at-risk patients is a clinical priority.
Read MoreNoninvasive Tests for NAFLD: Where Are We Now?NASH and Its Clinical Trials: Exciting Recent Developments
Patients with non-alcoholic fatty liver disease (NAFLD) are at risk of progressing to inflammatory non-alcoholic steatohepatitis (NASH), a NAFLD subtype associated with fibrosis, cirrhosis, and hepatocellular carcinoma.
Read MoreNASH and Its Clinical Trials: Exciting Recent DevelopmentsNASHmap: A New Non-invasive Tool for NASH Identification?
NASHmap, a non-invasive machine learning model, is revolutionizing NASH identification. Utilizing 14 clinical variables, it offers a promising alternative to invasive liver biopsies. With an 81% positive predictive value, NASHmap can potentially improve clinical practice and specialist referrals for high-risk patients.
Read MoreNASHmap: A New Non-invasive Tool for NASH Identification?Proteo-Transcriptomics for at-Risk NASH: The Future of Non-Invasive Risk Assessments?
Proteo-transcriptomic analyses offer a promising approach for precise NASH risk assessment. A predictive model based on protein levels and clinical variables demonstrates 79% accuracy. This innovative method holds potential for developing blood-based diagnostic tools. Further testing in diverse populations is necessary to validate its efficacy.
Read MoreProteo-Transcriptomics for at-Risk NASH: The Future of Non-Invasive Risk Assessments?The “Perfect” NASH Biomarker: An Unrealistic Pursuit?
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
Read MoreThe “Perfect” NASH Biomarker: An Unrealistic Pursuit?Cardiovascular Risk in Patients with NAFLD and Inflammatory Bowel Diseases
NAFLD's prevalence in IBD patients raises concerns for cardiovascular risk. The study found doubled atherosclerotic cardiovascular disease risk in IBD patients with NAFLD. Transient elastography may predict cardiovascular risk in IBD patients. Targeted risk assessments are crucial for IBD patients with NAFLD.
Read MoreCardiovascular Risk in Patients with NAFLD and Inflammatory Bowel DiseasesT2D-Related Complications and its Impact on Fibrosis Levels: An Emerging Association?
Patients with T2D complications have a 4.5x greater risk of developing fibrosis, independent of HbA1c levels. FIB-4 index can help identify diabetic patients at highest risk, improving primary care screening.
Read MoreT2D-Related Complications and its Impact on Fibrosis Levels: An Emerging Association?Fatty Liver Disease: A Key Predictor of Cardiac Dysfunction and Remodelling?
Fatty liver disease (FLD) is found to be the strongest independent predictor of increased heart rate and reduced left ventricular volumes, and positively predicts cardiac remodelling
Read MoreFatty Liver Disease: A Key Predictor of Cardiac Dysfunction and Remodelling?Surveillance in Patients with Non-cirrhotic NAFLD-related HCC: Obstacles and Solutions
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease encompassing simple hepatic steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC).
Read MoreSurveillance in Patients with Non-cirrhotic NAFLD-related HCC: Obstacles and SolutionsDr. S. Duarte graduated in Nutrition from the Universidade Paulista in 2007, got a Master in Clinical Gastroenterology Program at the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO in 2015 and became Doctor of Science in Gastroenterology from the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (2019) . He is currently a professor of undergraduate classes at Universidade Paulista. Has a background in nutrition, with a focus on gut microbiota assessment in Non-Alcoholic Fatty Liver Disease (NAFLD).
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES